Skip to main content
. 2019 Mar 1;12(3):1060–1069.

Figure 2.

Figure 2

The expression of Has2 is signifcantly down-regulated by miR-23. For evaluation of the effect of miR-23 on the levels of Has2 in BMSCs, the cells were randomly grouped (n = 4) and treated by miR-23 inhibitor, miR-23 mimic, shRNA-Has2, and the shRNA-Has2 + miR-23, respectively. A. RT-PCR analysis of miR-23 and Has2 in BMSCs after receiving of miR-23 inhibitor and miR-23 mimic, respectively. B. Detection of luciferase activity was conducted using the ELISA according to the manufacturer’s protocol. C. Western blot was applied to investigate the expression of Has2 in BMSCs after receiving of different treatment strategies. The left represents the qualitative images and the right represents the semi-quantitative analysis of the expression of Has2 in BMSCs post western blot. **P < 0.05, ***P < 0.01 compared to the cells treated by miR-23. ###P < 0.01 compared to the control cells.